The study of PPARβ/δ agonists demonstrates their role in obesity and IR diseases, such as hepatic ischemia/reperfusion injury through NF-κβ pathway inhibition, lipid adipocyte accumulation, and diabetic osteoporosis. The gene discussed is NFKB1; the disease is obesity due to melanocortin 4 receptor deficiency.